Clinical Trials Browser

Phase 3 × Has announcements × atezolizumab × Clear all

NCT05091567 2026-03-10

IMforte

Phase 3 Active not recruiting

660 enrolled 23 charts 1 FDA

Small Cell Lung Carcinoma

NCT03735121 2025-12-05

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 3 Completed

438 enrolled 40 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02908672 2025-07-20

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Phase 3 Completed

514 enrolled 25 charts 2 FDA

Melanoma

NCT03434379 2023-10-23

IMbrave150

Phase 3 Completed

558 enrolled 48 charts 2 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT02763579 2023-07-28

IMpower133

Phase 3 Completed

503 enrolled 23 charts 1 FDA

Small Cell Lung Carcinoma

NCT02409342 2023-03-15

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Phase 3 Completed

572 enrolled 32 charts 2 FDA

Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

NCT02425891 2022-07-19

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

Phase 3 Completed

902 enrolled 27 charts 1 FDA

Triple Negative Breast Neoplasms

NCT02367781 2021-08-09

IMpower130

Phase 3 Completed

723 enrolled 28 charts 1 FDA

Carcinoma